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CD8+ T lymphocytes play a major role in antiviral immune defense. Their significance for
acute hepatitis C is unclear. Our aim was to correlate the CD8+ T cell response with the
outcome of infection. Eighteen patients with acute hepatitis C and 19 normal donors were
studied. Hepatitis C virus (HCV)–specific CD8+ T cells were identified in the enzyme-linked
immunospot assay by their interferon-g (IFN-g) production after specific stimulation. The
highest numbers of IFN-g–producing HCV-specific CD8+ T cells were found in patients with
acute hepatitis C and a self-limited course of disease during the first 6 months after onset of
disease, but these numbers dropped thereafter to undetectable levels. The differences in re-
sponsiveness between patients with self-limited disease versus patients with a chronic course
were statistically significant ( ). Our data show that the number of IFN-g–producingP ! .001
HCV-specific CD8+ T cells during the first 6 months after onset of disease is associated with
eradication of the HCV infection.
A better knowledge of the role of hepatitis C virus (HCV)–
specific CD81 T lymphocytes is of great importance for the
understanding of the pathogenesis of HCV and the develop-
ment of new therapeutic strategies for chronic HCV infection.
In contrast to other viral infections, such as hepatitis B, in which
clearance of the virus during the acute phase of disease has
been shown to be associated with a strong polyclonal and multi-
specific cytotoxic T cell response [1, 2], the frequency and sig-
nificance of HCV-specific CD81 T cells for viral clearance in
acute hepatitis C (aHCV) is unknown. A comparison of the
virus-specific CD81 T cell response in patients with acute self-
limited disease versus that in patients with chronic hepatitis C
infection may lead to a better understanding of the role of CD81
T lymphocytes in viral elimination during hepatitis C infection.
Recently, several new methods for determining a specific
CD81 T lymphocyte response have been developed and have
yielded new insights into the function and kinetics of a virus-
specific CD81 T cell response [3–5]. Two of the methods mea-
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sure the interferon-g (IFN-g) production of CD81 T cells after
stimulation with viral peptide. The CD81 T cell numbers are
determined either by measuring secreted IFN-g with the en-
zyme-linked immunospot (ELISPOT) assay or by cytoplasmic
staining for IFN-g and subsequent fluorescence-activated cell-
scanning analysis. The third available measurement method
enumerates antigen-specific cytotoxic T lymphocytes (CTLs) by
direct staining of virus-specific CD81 T cells by use of tetrameric
complexes of major histocompatibility complex class I glyco-
protein plus viral peptide. The data published for human im-
munodeficiency virus (HIV) and lymphocytic choriomeningitis
virus (LCMV) showed that the numbers of identified CD81 T
lymphocytes are similar with the 3 methods and are higher than
the numbers derived from limiting dilution analysis and 51chro-
mium (51Cr)–release assay. Among other explanations, this dif-
ference may be attributable to the fact that 51Cr-release assays
require 1 or several steps of in vitro restimulation, which pref-
erentially lead to expansion of resting memory CTLs, whereas
the ELISPOT assay allows detection of finally differentiated
effector CTLs, which means that this assay may more accu-
rately reflect the in vivo situation [3–7]. We have chosen to
apply the ELISPOT assay, which has been suggested as a can-
didate for the gold standard in terms of its ability to quantify
CD81 T cells [8], in order to study HCV-specific CD81 T cells.
The present study addresses the question of whether there is
a correlation between the occurrence of HCV-specific CD81 T
lymphocytes and the outcome of infection. To identify the IFN-
g response of virus-specific CD81 T lymphocytes, a panel of
previously described HCV-specific epitopes [9–17] was used fors
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Table 1. Patient characteristics.
Patient Sex
Age,
years
HLA
class I Outcome
Peak,
ALT U/L
ALT U/L at
date of assay
Time between
aHCV and assay,
months Therapy
1 M 41 A2, B7 Self-limited 1174 18, 13, 15 6, 9, 13 No
2 F 57 B7 Self-limited 581 12, 10 11, 25 No
3 F 37 B7 Self-limited 828 11 10 No
4 F 42 B8 Self-limited 1728 8, 6, 6 4, 9, 20 No
5 M 47 B7 Self-limited 792 9 4 No
6 M 42 A2, B8 Self-limited 1466 12 6 No
7 F 17 A2 Self-limited 1140 10, 10 2, 10 No
8 M 35 A2, B7 Self-limited 659 659, 15 2, 8 No
9 M 30 A2 Self-limited 1546 1546, 15 2, 7 No
10 F 35 B8 Pending 2232 152, 32, 77 1, 2, 3 No
11 F 34 A2, B7 Relapsed 958 958 1 No
12 M 39 A2, B7 Relapsed 987 62, 42 5, 8 No
13 M 64 A2 Relapsed 949 29, 385 2, 7 No
14 F 64 A2 Relapsed 1730 147, 509 1, 7 No
15 F 55 A2 Chronic 850 850, 24 1, 8 Yes
16 F 75 A2 Chronic 1514 1514 1 No
17 M 21 A2, B7 Chronic 580 431, 18 1, 8 Yes
18 M 57 A2 Chronic 710 141, 184 1, 7 No
NOTE. aHCV, acute hepatitis C virus; ALT, alanine aminotransferase; F, female; M, male.
stimulation of peripheral blood mononuclear cells (PBMC) in
18 patients with aHCV infection, and the IFN-g production of
CD81 T lymphocytes was measured in the ELISPOT assay. As
controls, 19 normal donors were tested according to the pro-
tocols used to test the patients. Our results show that viral
clearance and resolution of disease in aHCV infection is as-
sociated with the occurrence of HCV-specific CD81 T cells dur-
ing the first 6 months after onset of disease. The ELISPOT
assay proved to be a powerful tool for identifying and enu-
merating virus-specific CD81 T cells.
Materials and Methods
Patients. Thirty-seven HLA class I–typed individuals were
studied (9 patients with aHCV and a self-limited course, 4 patients
with aHCV who became temporarily negative for HCV RNA, 4
patients with aHCV and a primarily chronic course of disease, 1
patient with aHCV and a follow-up within less than 6 months [table
1], and 19 normal donors). The diagnosis of aHCV was based on
the following criteria: (1) elevated serum alanine aminotransferase
levels—levels that were >20 times above the upper limit of normal;
(2) seroconversion of anti-HCV–negative to anti-HCV–positive an-
tibody status by second- or third-generation enzyme-linked im-
munosorbent assay or recombinant immunoblot assay II; (3) pos-
itive polymerase chain reaction (PCR) for HCV RNA in at least
the first serum sample (by use of nested PCR [detection limit, 200
eq/mL]); and (4) history of sudden onset of liver disease in previ-
ously healthy persons. Other possible causes of acute hepatitis, such
as other viral hepatitis, autoimmune hepatitis, alcoholic liver dis-
ease, or toxins, have been excluded.
The following 3 groups of patients and a control group were
included in the study: (1) patients with aHCV who eliminated the
virus permanently and who had a self-limited course of disease;
(2) patients with aHCV who became transiently negative for HCV
RNA during the first 6 months of disease but who were positive
for HCV RNA after 6 months follow-up and who developed
chronic infection; (3) patients with aHCV and a chronic course of
disease; and (4) normal donors. All normal donors were HCV
seronegative.
Isolation of PBMC and proliferation assay. Human PBMC
were isolated from heparinized blood by Ficoll-paque density-gra-
dient centrifugation. Briefly, PBMC were washed 4 times in phos-
phate-buffered saline (PBS) and were resuspended in tissue-cultured
medium (RPMI 1640 medium; Gibco, Grand Island, NY) con-
taining 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U of
penicillin/mL, 100 mg of streptomycin/mL, and 10% human AB
serum.
PBMC were incubated at /well in 96 U-bottom plates45 3 10
(Costar, Cambridge, MA) for 5 days in the presence of HCV pro-
teins (1 mg/mL) in 150 mL tissue culture medium. On day 5, cultures
were labeled by incubation for 16 h with 2 mCi 3H-thymidine (spe-
cific activity, 80 mCi/mM; Amersham, Buckinghamshire, United
Kingdom). Cells were then collected and washed on filters (Dunn,
Asbach, Germany) by use of a cell harvester (Skatron, Sterling,
VA), and the amount of radiolabel incorporated into DNA was
estimated by use of a beta counter (LKB/Pharmacia, Uppsala,
Sweden). Triplicate cultures were routinely assayed, and the results
are expressed as mean counts per minute (cpm). The stimulation
index (SI) was calculated as the ratio between cpm obtained in the
presence of antigen and that obtained without antigen. An SI >3
was considered significant.
HCV proteins. Recombinant proteins for antigenic stimulation
of CD41 T lymphocytes were kindly provided by M. Houghton
(Chiron, Emeryville, CA), and these proteins comprised the antigen
c200 (nonstructural protein NS3 1 NS4). All antigens were ex-
pressed as COOH-terminal fusion proteins with human superoxide
dismutase (SOD) in yeast. Yeast and SOD were tested as controls
in each proliferation assay for unspecific stimulation. The purity
of the antigens ranged from 80% to 90%.
Synthetic peptides. A panel of peptides that represents 19 pre-
viously identified HLA A2-, B7-, and B8-restricted HCV CTL epi-
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Table 2. Epitopes (cutoff for a positive response was assessed in normal donors and is indicated
as no. of specific spots).
Protein
Amino acid
position Amino acid sequence
Strain
or type
HLA
class I
Peptide
no.
Positive cutoff
(specific spots) Reference
Core 35–44 YLLPRRGPRL HCV-1 A2 1 11 [9, 10]
131–140 ADLMGYIPLV HCV-1 A2 2 10 [10]
E1 220–227 ILHTPGCV HCV-H A2 3 9 [15]
257–266 QLRRIDLLV HCV-1 A2 4 7 [16]
363–371 SMVGNWAKV HCV-H A2 5 10 [15]
E2 401–411 SLLAPGAKQNV HCV-1 A2 6 8 [15]
NS3 1073–1081 CINGVCWTV HCV-1 A2 7 12 [10]
1169–1177 LLCPAGHAV HCV-1 A2 8 14 [10]
1287–1296 TGAPVTYSTY HCV-BK A2 9 20 [14]
1406–1415 KLVALGINAV HCV-1 A2 10 7 [10]
NS4 1789–1797 SLMAFTAAV HCV-1 A2 11 4 [10]
1807–1816 LLFNILGGWV HCV-1 A2 12 5 [9, 10]
NS4B 1851–1859 ILAGYGAGV HCV-1 A2 13 13 [9]
NS5 2252–2260 ILDSFDPLV HCV-1 A2 14 5 [10]
NS5B 2578–2587 RLIVFPDLGV HCV-1 A2 15 6 [9]
2727–2735 GLQDCTMLV HCV-1 A2 16 11 [9]
Core 41–49 GPRLGFRAT HCV-1 B7 17 12 [12]
111–119 DPRRRSRNL HCV-1 B7 18 8 [17]
NS3 1395–1403 HSKKKCDEL HCV-1 B8 19 10 [13]
NOTE. HCV, hepatitis C virus; NS, nonstructural protein.
topes [9–17] were selected for this study (table 2). All peptides were
synthesized with a free amine NH2-terminus and a free acid
COOH-terminus by Chiron Mimotopes (Clayton, Australia). Lyo-
philized peptides were reconstituted at 20 mg/mL in dimethyl sulf-
oxide (Mallinckrodt, Paris, KY) and were diluted to 1 mg/mL with
RPMI 1640 medium (Gibco).
HLA typing. HLA class I typing of subjects was performed
on fresh PBMC by the Immunogenetics Laboratory (University of
Munich) using standard serologic techniques.
ELISPOT assay. Nitrocellulose-bottom 96-well millititer HA
plates (Millipore, Bedford, MA) were coated with 100 mL of the
IFN-g monoclonal antibody (anti–IFN-g; Mabtech AB, S-10405,
Stockholm, Sweden), at a concentration of 15 mg/mL, in PBS and
were incubated overnight at 47C. Unbound antibodies were re-
moved via 4 successive washings with PBS containing 0.05 Tween.
The coated wells were filled in duplicate with 100 mL of RPMI
medium containing freshly isolated PBMC, together with52 3 10
the respective HCV peptide (20 mg/mL) or phytohemagglutinin
(PHA) (5 mg/mL), and samples were incubated (undisturbed) for
48 h at 377C in a humidified atmosphere with 5% CO2.
After incubation, the cells were removed by washing the plates
4 times with PBS. One hundred microliters of the biotin-conjugated
anti–IFN-g (Mabtech AB) was added to each well at a dilution of
1 mg/mL and incubated for 4 h at room temperature. The plates
were rinsed 4 times by immersion in PBS and were exposed to 100
mL of streptavidin–alkaline phosphatase (Mabtech AB) for 1 h.
Unbound conjugate was removed by washing thoroughly with PBS,
and, finally, 100 mL of 5-bromo-4-chloro-3-indolylphosphate/ni-
troblue tetrazolium substrate solution (Bio-Rad Laboratories,
Richmond, CA) was added, and the sample was incubated for 2
h. The color reaction was stopped by extensive washings under
running water, and after drying, the number of spots was scored
by use of a dissection microscope. Stimulation with PHA was used
as a positive control.
Statistical analysis. Analysis of differences among the 3 patient
groups and between groups A and B was accomplished by use of
the x2 test, the Fisher exact test, and the Wilcoxon signed rank
test, respectively. For statistical analysis, the results are calculated
as specific spots (number of spots in the presence of HCV peptide
minus the number of spots without peptide) as follows: nonspecific
spots, all individuals tested (median, 1; range, 0–11); patients with
acute self-limited hepatitis C (median, 1; range, 0–10); patients with
aHCV who became temporarily negative for HCV RNA (median,
1; range, 0–5); and patients with aHCV and a primary chronic
course of disease (median, 1; range, 0–11). No statistical difference
related to the number of nonspecific spots was found among the
different groups (Kruskal-Wallis test).
In order to exclude artifacts, only tests within the 95% confidence
interval for negative and positive controls were considered for
evaluation. Specific spots greater than the mean control (12 SD)
for the peptides in normal donors were required to be considered
positive or significant. The cutoffs for each peptide are indicated
in table 2.
Characterization of effectors by specific cell-depletion studies.
CD41 and CD81 T cells were depleted according to the manufac-
turer’s instructions. Briefly, 107cells were depleted by incubation
with 20 mL of anti-CD4 or anti-CD8 monoclonal antibody con-
jugated to ferrous beads (MACS MicroBeads; Miltenyi Biotec, Ber-
gisch Gladbach, Germany) in 80 mL of buffer (PBS containing 2
mM EDTA and 0.5% bovine serum albumin) at 47C for 30 min.
After incubation, the cells were washed, the supernatant was re-
moved, and the cell pellet was resuspended in 500 mL buffer. The
conjugate-coated cells were removed by passing through a positive
selection column type LS1/VS1 placed in the magnetic field of a
magnet (MidiMACS, Miltenyi Biotec). Cells eluted from the bot-
tom of the column were treated as CD82 and CD42 fractions,
respectively. The beads used here reliably deplete 199% of the target
cell population. Purity of the cell fractions was confirmed by flow
cytometric analysis (data not shown).
Characterization of effectors by anti-CD8–blocking assay. To
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Figure 1. A–C, Enzyme-linked immunospot (ELISPOT) results for patients with HLA A2. Peripheral blood mononuclear cells (PBMC) from
13 patients were stimulated with 20 mg/mL of HLA A2–restricted peptides for 48 h, and the interferon-g production was measured in the ELISPOT
assay as described in Materials and Methods. Each bar represents the specific spots/ PBMC. The numbers on the abscissa indicate the52 3 10
peptides used (table 2). Specific spots greater than the mean control (12 SD) for the peptides in normal donors were required before the results
were considered positive. Two time points (!6 months and >6 months) for each patient are shown.
further characterize the cell population stained in the ELISPOT
assay, the contribution of CD81 T cells to the IFN-g production
in the ELISPOT assay was determined by incubating PBMC with
anti-CD8 antibody (Coulter Immunotech, Marseille, France) at
47C for 60 min before addition to the ELISPOT assay. After in-
cubation, the cells were washed and resuspended in culture medium.
Results
ELISPOT results for patients with aHCV and a self-limited
course. The highest numbers of positive responses were seen
during the first 6 months after onset of disease in patients with
aHCV and a self-limited course. Four of 5 patients with HLA
A2 showed peripheral CD81 T cells with effector function
within 48 h of T-cell–receptor occupancy with 11 HCV peptide,
representing a multispecific and significant response during the
first 6 months after onset of disease. This responsiveness was
directed against structural, as well as nonstructural, epitopes.
A follow-up testing between 6 and 12 months after onset of
disease was possible in 4 of these patients. The responsiveness
seen in the early phase is no longer detectable in 3 of 4 patients
or has dropped to borderline positivity in 1 of them (figure 1A).
Patient 6 was lost to follow-up.
Five patients with acute self-limited hepatitis C and HLA B7
could be tested (figure 2A). Positive responses were seen during
the first 6 months after onset of disease in patients 1 and 8.
For patients 2 and 3, the response was seen between 6 and 12
months after onset of disease. During the first 6 months after
1532 Grüner et al. JID 2000;181 (May)
Figure 2. A and B, Enzyme-linked immunospot (ELISPOT) results for patients with HLA B7 and B8. Peripheral blood mononuclear cells
(PBMC) from 7 patients were stimulated with 20 mg/mL of HLA B7–restricted (3 time points are shown for each patient) or HLA B8–restricted
(3 time points are shown for each patient) peptides for 48 h, and the interferon-g production was measured in the ELISPOT assay as described
in Materials and Methods. Each bar represents the specific spots/ PBMC. Nos. on the abscissa indicate the peptides used (table 2). Specific52 3 10
spots greater than the mean control (12 SDs) for the peptides in normal donors were required before the results were considered positive. NT,
not tested.
onset of disease, no PBMC were available for these 2 patients.
Patients 1 and 2 were tested 11 year after onset, and no sig-
nificant response was detectable at that point. Patient 3 was
lost to follow-up (figure 2A).
For patients with HLA B8 (total of 2 patients), 1 patient
with self-limited disease and 1 patient with a follow-up of 3
months (outcome to be determined) were tested (figure 2B).
Patient 4 had a significant response to the HLA B8 epitope
NS3 1395-1403 during the first 6 months. More than 6 months
after onset of disease, this response dropped below the level of
significance. For patient 10 (during the first 6 months after
onset of disease) a significant response was also found, and this
response declined over the course of time to a level that was
below the level of significance (figure 2B).
ELISPOT results for patients with aHCV and a chronic
course. During the first 6 months after onset of disease, 1 of
4 patients with HLA A2 had a bispecific response (patient 18).
Between 6 and 12 months after onset of disease, 2 patients who
had no response during the first 6 months after onset of disease
had a monospecific or multispecific response under specific
treatment (patients 15 and 17). Patient 15 started with IFN and
ribavirin 6 months after onset of disease, and patient 17 started
with IFN monotherapy 3 months after onset of disease. Patient
18, who had a bispecific response at the beginning, displayed
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Table 3. No. of positive responses (in relation to total tests per-
formed) for HLA A2–restricted epitopes for patients with acute hep-
atitis C and self-limited, relapsed, or chronic course of disease during
the first 6 months after onset of disease.
Epitopes
HLA
restriction
Self-
limited Relapsed Chronic
Peptide
no.
Core 35–44 A2 2/5 0/4 0/4 1
Core 131–140 A2 3/5 1/4 0/4 2
E1 220–227 A2 1/5 0/4 1/4 3
E1 257–266 A2 3/5 0/4 1/4 4
E1 363–371 A2 1/5 1/4 0/4 5
E2 401–411 A2 2/5 0/4 0/4 6
NS3 1073–1081 A2 2/5 1/4 0/4 7
NS3 1169–1177 A2 0/5 1/4 0/4 8
NS3 1287–1296 A2 0/5 0/4 0/4 9
NS3 1406–1415 A2 3/5 0/4 0/4 10
NS4 1789–1797 A2 3/5 1/4 0/4 11
NS4 1807–1816 A2 2/5 1/4 0/4 12
NS4B 1851–1859 A2 3/5 0/4 0/4 13
NS5 2252–2260 A2 3/5 1/4 0/4 14
NS5B 2578–2587 A2 2/5 1/4 0/4 15
NS5B 2727–2735 A2 2/5 0/4 0/4 16
NOTE. NS, nonstructural protein.
Figure 3. Interferon-g production on stimulation with HLA class
I–restricted hepatitis C virus (HCV) epitope and without stimulation
in a 48-h enzyme-linked immunospot assay before and after depletion
of CD41 or CD81 T cells. Each bar represents the spots/ cells,52 3 10
predepletion.
a monospecific response 7 months after onset of disease (figure
1C). Patient 16 was lost to follow-up.
Since the timing of the assay might have been crucial, assays
were performed, if possible, at several time points. However,
in our experience and because of the special characteristics of
this patient group, material from patients with aHCV could
not be supplied on a regular basis, and patients with self-limited
disease in particular are not always involved in a close follow-
up practice. Therefore, we tested different time points in the
patient groups. We decided to present the first available assay
because it offers a clear presentation and comparability. For
patients 15–17, assays at 2, 3, and 4 months were also per-
formed, and these assays were always negative. Thus, the dif-
ferences among the patient groups cannot be explained by dif-
ferent timing of assays.
ELISPOT results for patients with aHCV and transiently neg-
ative HCV RNA. Patients with aHCV, in whom HCV RNA
was transiently undetectable and in whom transaminases were
normalized during the first 6 months but who subsequently
relapsed, with positive RNA in serum and elevated transami-
nases, were considered as a separate group. All of these patients
relapsed between 3 and 4 months after onset of aHCV. During
the first 6 months after onset of disease, 1 of 4 patients had a
multispecific response, and 1 patient had a monospecific re-
sponse. Between 6 and 12 months after onset of disease, patient
12 still had a multispecific response, and patient 14 had a bor-
derline multispecific response. For patient 13, no responsiveness
could be detected. Patient 11 was lost to follow-up. Patient 14
was studied in the negative phase of HCV RNA. Patients 11,
12, and 13 were studied in the HCV-RNA–positive phase (figure
1B).
ELISPOT results for normal donors. Either zero cells or
!10 HCV-specific IFN-g–secreting cells/ PBMC were52 3 10
observed in the presence of HLA-matched HCV-specific pep-
tides in 17 of 19 normal donors. In 1 of the normal donors we
detected 110 specific cells/ PBMC (representing a pos-52 3 10
itive response) to 5 of the HCV-specific epitopes (range, 11–22
specific spots). These epitopes were located in NS3, NS4B, and
NS5B. In 1 normal donor, we observed 30 specific spots to
peptide E1 363-371 but no specific spots to the remaining 15
HLA A2 peptides tested in this person.
Previous studies demonstrated that because each spot in the
ELISPOT assay represents the cytokine molecules secreted by
a single cell, an enumeration of the frequency of effector CD81
T cells is possible. The highest frequencies of CD81 T cells
specific for 1 HCV peptide in our patients with self-limited
disease reached up to 0.2% of all peripheral CD81 T cells. Since
the responses had a multispecific pattern, the percentage of
peripheral CD81 T cells specific for all of the HCV peptides is
supposed to be much higher.
In summary, during the first 6 months, the differences in
responsiveness for patients with HLA A2 and self-limited dis-
ease versus patients with a chronic course of disease (P !
) or versus patients with transiently negative HCV RNA.001
( ) were statistically significant. The difference betweenP ! .001
patients with a primary chronic course of disease versus patients
with transiently negative HCV RNA ( ) failed to proveP = .052
significance (table 3).
Characterization of effectors. The IFN-g–secreting cells
could be blocked by anti-CD8 antibody, consistent with the
expectation that the production of IFN-g was mediated by
CD81 T cells (data not shown). Moreover, depletion of CD81
T cells from fresh PBMC completely abrogated the HCV-
specific responses. Conversely, depletion of CD41 cells did not
diminish the number of IFN-g–secreting cells (figure 3).
Correlation of the CD41/CD81 T cell response. Addition-
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Figure 4. Proliferative CD41 T cell response for patients with (group
A) and without (group B) a significant CD81 T cell response during
the first 6 months after onset of acute hepatitis C virus to recombinant
HCV proteins NS3 and NS4 (C-200 Chiron). Results are shown as
stimulation index (SI) = 3H-thymidine incorporation of antigen-stim-
ulated peripheral blood mononuclear cells (count per minute [cpm])/
unstimulated control (cpm). Values >3 are considered significant.
ally, the CD41 T cell response to recombinant NS3 and NS4
protein was assessed at identical time points in parallel to the
CD81 T cell response in certain cases. Interestingly, except for
1 assay, all patients with a significant CD81 T cell response
also showed a significant CD41 T cell response at the same
time (figure 4). As described recently by Gerlach et al. [18], the
CD41 T cell response was maintained only in patients with a
self-limited course of disease (data not shown). The CD81 T
cell response waned to undetectable levels in these patients (fig-
ures 1 and 2).
Discussion
The current study was performed to analyze a potential as-
sociation between the HCV-specific CD81 T cell response and
the course of aHCV infection. As a main result, we found a
significant difference during the first 6 months after onset of
disease, in terms of responsiveness to a set of HLA-matched
HCV-specific CTL peptides, between patients with aHCV and
a self-limited course and those with a chronic course of disease.
During the first 6 months after onset of disease in patients
with aHCV, a significant CD81 T cell response directed against
multiple class I–restricted HCV epitopes of different regions of
the HCV polyprotein correlated with termination of the disease.
Four of 5 patients with HLA A2 and a self-limited course of
aHCV had positive multispecific responses (during the first 6
months after onset of disease) against structural, as well as
nonstructural, HCV epitopes. The significant responsiveness
seen during the first 6 months after onset of disease in patients
with acute self-limited disease was restricted to this phase and
thereafter dropped to undetectable levels. A similar pattern in
responsiveness was found in patients with HLA B7 and B8.
After viral clearance, no significant difference between the dif-
ferent patient groups was detectable. Calculating the frequency
of peripheral HCV-specific CD81 T cells, percentages of up to
0.2% of the CD81 T cells were found to be specific for 1 HCV
peptide. Recent data for patients with chronic HCV infection
have revealed that the frequencies of intrahepatic HCV-specific
CD81 T cells are up to 190-fold higher than the peripheral
frequencies [19]. Since liver biopsies are contraindicated in pa-
tients with aHCV, studies of the HCV-specific CD81 T cell
response have to rely on blood samples that contain far fewer
HCV-specific CD81 T cells. However, by extrapolating the fre-
quencies found in our patients, one can speculate that the fre-
quencies of CD81 T cells specific for 1 peptide in the liver of
patients with aHCV and a self-limited course could be in the
range of 2% of all CD81 T cells, assuming that the intrahepatic
frequencies are 10-fold higher than in the peripheral blood.
Furthermore, taking into consideration that the responses are
multispecific (e.g., patient 6 with 10 epitopes recognized in the
peripheral blood), it is possible that the majority of intrahepatic
CD81 T cells are HCV-specific CD81 T cells and not unspecific
bystander cells. Most likely these numbers still underestimate
the total numbers of HCV-specific CD81 T cells in the periph-
eral blood, as well as in the liver, for several reasons. First, the
peptides used for stimulation cover only part of the HCV ge-
nome and of the potential viral epitopes capable of inducing a
CD81 T cell response. There are certainly CD81 T lymphocyte
specificities that are different from the known ones that are
relevant during infection. Second, viral epitopes used for stimu-
lation covered (with their binding motif) only some HLA types,
although a cross-reactivity has been shown for several of the
presented epitopes [20]. Third, nonreactivity related to sequence
difference in the peptides used for stimulation and in the epi-
topes of the individual patients due to mutations or different
HCV strains cannot be ruled out.
In patients with aHCV and a chronic course of disease, only
1 bispecific response was found during the first 6 months after
onset of disease. Interestingly, 1 patient mounted a monospe-
cific response and another a multispecific response under spe-
cific treatment. Of the patients who only transiently cleared the
virus, 1 patient displayed a monospecific response and 1 patient
a multispecific response when tested in the first 6 months. Like
patient 18, who had a chronic course, the response in patient
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12 seemed to increase over time, despite the reappearance of
the virus. This observation is also supported by observations
in chimpanzee studies, in which CTL responses tended to wane
after HCV resolution but gradually expanded in persistent in-
fection [21].
Together our results support recent studies in chimpanzees,
which showed that a CTL response broadly directed against
multiple epitopes is required for the resolution of aHCV, and
indicate that critical factors for resolution are the number of
specificities of the CD81 T cells that are synchronously opera-
tional in early infection. This might lower the likelihood of
viral escape [21].
Of 19 normal donors, 1 displayed a response against struc-
tural and nonstructural HCV epitopes. Another had a positive
response directed against 1 E1 epitope. The presence of virus-
specific CD81 T cells in healthy donors, which has been found
in a minority of these individuals, suggests either previous ex-
posure to HCV or cross-reactivity to other infectious agents.
The detection of virus-specific CD81 T cells by ELISPOT assay
has recently been described by Scognamiglio et al. in HCV-
negative healthy family members of patients with chronic HCV
infection [22]. Scognamiglio et al. suggested that virus-specific
CTL effectors in normal donors may provide protective im-
munological memory and that the latter requires continuous
stimulation by persisting antigen, which either stems from un-
detectable viral antigen or represents cross-reactivity to self-
antigens.
The CD41 T cell response to NS3 and NS4 protein was
measured at identical time points, as was the CD8 T cell re-
sponse. The fact that a CD81 T cell response was seen almost
exclusively in the face of a strong CD41 T cell response suggests
that a significant CD41 T cell response is required to mount a
detectable CD81 T cell response. These data are in line with
recent observations that CD41 T cells are needed to enable
CD81 T cells (via antigen-presenting cells) to be activated [23,
24].
In summary, our data indicate that a positive and multi-
specific CD81 T cell response during the first 6 months after
onset of disease is associated with eradication of HCV infection.
Our data also suggest that this response is required to control
the disease. A significant and coordinated CD41 T cell response
seems to be a prerequisite for the CD81 T cell response. The
mechanisms of IFN-g by which this control is mediated (i.e.,
direct killing of infected cells or interference with viral genome
expression, as has been shown in HBV [25]) remains to be
clarified. Moreover, the results confirm previous data in HIV
and LCMV [4–7] that new technologies, such as the ELISPOT
assay, are a powerful tool for use in the analysis and enumer-
ation of virus-specific CD81 T cells (a tool that does not require
long-term in vitro culture). However, in future studies it will
be interesting to compare the ELISPOT results with CTL 51Cr-
release assays in identical patients. The present data contribute
to a better understanding of the virus-host interaction and are
a prerequisite for the development of new therapeutic strategies,
such as peptide-based or DNA-based vaccines.
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